Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

a in situ (AIS)), cervical pre-cancers (cervical intraepithelial neoplasia (CIN) grade 2), vulvar pre-cancers (vulvar intraepithelial neoplasia (VIN) 2/3) and vaginal pre-cancers (vaginal intraepithelial neoplasia (VaIN) 2/3), and for the prevention of genital warts and low-grade cervical lesions (CIN 1) caused by HPV types 6, 11, 16 and 18. GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine.

High grade vulvar and vaginal lesions indicators for possible development of cancer

The studies used for this analysis combine findings from one phase II study and two phase III studies - Protocol 007, Protocol 013 (FUTURE I) and Protocol 015 (FUTURE II), respectively. All three studies were double-blind, placebo-controlled randomized studies and were conducted at 157 sites in 24 countries. More than 18,000 women participated in the three trials and were between the ages of 16 to 26 at the time of enrollment. They received three doses of either GARDASIL or placebo at day one, month two and month six. The combined analysis evaluated the impact of GARDASIL on the incidence of high-grade vulvar and vaginal pre-cancers (VIN 2/3 and VaIN 2/3), common precursors to vulvar and vaginal cancers in younger women, caused by HPV types 16 and 18.

In the per-protocol population of this combined analysis, GARDASIL was 100 percent effective in preventing HPV 16- and 18-related VIN 2/3 and VaIN 2/3 in women who were not exposed to the relevant HPV types until at least one month after completing the vaccination series; no cases were observed in the vaccine group (n=7,811) compared to 15 cases in the placebo group (n=7,785).

In the unrestricted population of this combined analysis, GARDASIL was 97 percent effective in preventing HPV 16- and 18-related VIN 2/3 and VaIN 2/3 in women who may have been exposed to the relevant HPV types before completing the vaccination series; one case was o
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:7/29/2014)...  Instrumentation Laboratory (IL) today announced the launch of its ... is part of a comprehensive rebranding effort by Werfen, the ... Boston, MA , in 1959, IL has been part ... companies in the group include Inova Diagnostics ( San ... Spain ).  Like IL, these three companies are focused ...
(Date:7/29/2014)... WESTFORD, Mass., July 29, 2014 Cynosure, ... and markets laser- and light-based aesthetic treatment systems for ... months ended June 30, 2014. Second-quarter 2014 financial results ... completed on June 24, 2013. ... revenues increased 45% to $72.6 million , Non-GAAP ...
(Date:7/29/2014)... 2014  Ambit Biosciences (Nasdaq: AMBI ), a ... targeting unmet needs in oncology, autoimmune and inflammatory disease, ... after closing of the NASDAQ Global Market on Tuesday, ... hosted by Michael Martino , president and CEO, ... on the same day at 5:00 pm EDT (2:00 ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Ambit Biosciences To Announce Second Quarter 2014 Financial Results 2
... The New England Journal of Medicine today released a study entitled, ... discussed in the report were brought by Phillips & Cohen LLP, a law ... Phillips & Cohen has specialized in representing whistleblowers for more than 20 years. ... Comments from Erika ...
... , May 12 The U.S. Food and Drug Administration is ... Itch Stopping Gel, an over-the-counter (OTC) product that should only be used on ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ... The FDA has received reports ...
Cached Medicine Technology:Whistleblower Lawyers Comment on New England Journal of Medicine Study 2Whistleblower Lawyers Comment on New England Journal of Medicine Study 3FDA: Serious Side Effects from Swallowing Topical Benadryl Product 2FDA: Serious Side Effects from Swallowing Topical Benadryl Product 3
(Date:7/29/2014)... Merrick, NY (PRWEB) July 29, 2014 Summer is ... whether that means enjoying a hike, swimming in a pool or ... it’s time for fleas and ticks. The Puppy Store is here ... during the summer months. , It’s almost impossible to completely keep ... can take to minimize the chances of their pets coming into ...
(Date:7/29/2014)... 29, 2014 A team of scientists, ... Ethell, PhD, has developed a blood test for Alzheimer’s ... the development of Alzheimer’s disease interventions, according to an ... a puzzle, and this study represents one of several ... the past couple of years,” Ethell said. , The ...
(Date:7/29/2014)... best way to cure most cases of cancer is ... this approach, however, is that the surgeon may fail ... recurrence. , With a new technique, researchers at the ... help surgeons see the entire tumor in the patient, ... relies on an injectable dye that accumulates in cancerous ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 As testosterone ... U.S. courts, Bernstein Liebhard LLP notes that a new ... men with Type 2 diabetes. The research, which was ... Metabolism on June 30th, involved 88 men who suffered ... to moderate aging male symptoms and erectile dysfunction. Roughly ...
(Date:7/29/2014)... America (GSA) and the National Center for Creative ... Columbia University as the 2014 recipient of the Gene ... This award recognizes and honors the seminal work of ... creativity and aging shifted the conceptual focus from a ... inspired individuals to approach longevity asking what wonders can ...
Breaking Medicine News(10 mins):Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Charon to receive 2014 Gene D. Cohen Award 2
... (Nasdaq: NUTR ) today reported results for the ... sales for the fiscal 2009 first quarter were $39.6 million ... 2008. For the first quarter of fiscal 2009, net ... compared to net income of $3.2 million, or $0.28 diluted ...
... MOUNTAIN VIEW, Calif., Jan. 29 Concentric Medical, ... removal in ischemic stroke patients, today announced the ... of the Outreach(TM) Distal Access Catheter for use ... Catheter provides neurointerventionalists additional access and support options ...
... growing list of Ancient Minerals international distributors. , ... ... Inc. announced today that Australian company Rejuve Health Products Pty Ltd. ... of Ancient Minerals topical magnesium products. Located in Buderim, Queensland, the ...
... the National Association of Medicaid Fraud Control Units ... has joined the Whistleblower Action Network through his ... Carson City, Nevada. The Whistleblower Action Network ... citizens, known as "relators," who witness fraud against ...
... France, January 29 , - A New Year ... Excluding the Currency Effect, - Higher Earnings Expected ... ophthalmic optics, today,announced consolidated revenue of EUR3,074.5 million for the year ... Excluding the currency effect, growth for the year was a strong ...
... Researchers from Boston University School of Medicine (BUSM) and ... have found that children born more than three months premature, ... the modified checklist for autism in toddlers (M-CHAT). Children ... for developing autism. These findings appear in the January ...
Cached Medicine News:Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 2Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 3Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 4Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 5Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 6Health News:Nutraceutical Reports Fiscal 2009 Q1 Results 7Health News:Concentric Medical Expands Product Offering in Neuro Access 2Health News:The Healing Power of Ancient Minerals Magnesium Oil Now Available Down Under 2Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 2Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 3Health News:Nationally Recognized Medicaid Fraud Prosecutor Tim Terry Joins Successful Whistleblower Law Practice, Specializing in "Qui Tam" Citizen Suits Under False Claims Acts 4Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6Health News:Study finds preemies more likely to score positive 2
... ENDOPATH EZ45 Endoscopic Linear Cutter has application ... surgical procedures for transection, resection, and/or creation ... staple line or tissue buttressing materials such ... reloaded seven times for a total of ...
... Linear Cutters provide a 45mm staple and ... the device suitable for many minimally invasive ... transection, resection, and/or creation of anastomoses in ... ,The LONG45A Endocutter has a shaft ...
ACUCLIP Endoscopic Right-Angle Multiple Clip Applier, 10 mm Shaft Diameter with 20, 8 mm Titanium Clips...
Insert only, Pilling-Weck medium clip size...
Medicine Products: